

# Samy Hadjadj

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1010193/publications.pdf>

Version: 2024-02-01

65  
papers

2,540  
citations

201674

27  
h-index

206112

48  
g-index

67  
all docs

67  
docs citations

67  
times ranked

4534  
citing authors

#	ARTICLE	IF	CITATIONS
1	History of bariatric surgery and COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. <i>Obesity</i> , 2022, 30, 599-605.	3.0	7
2	Influenza vaccination and prognosis for COVID-19 in hospitalized patients with diabetes: Results from the CORONADO study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 343-347.	4.4	2
3	Association Between the ACE Insertion/Deletion Polymorphism and Risk of Lower-Limb Amputation in Patients With Long-Standing Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 407-415.	8.6	3
4	COVID-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study. <i>Current Diabetes Reports</i> , 2022, 22, 53-63.	4.2	14
5	Association of statin and/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102484.	3.6	6
6	Differential prognostic burden of cardiovascular disease and lower-limb amputation on the risk of all-cause death in people with long-standing type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2022, 21, 71.	6.8	2
7	Impact of diabetes on COVID-19 prognosis beyond comorbidity burden: the CORONADO initiative. <i>Diabetologia</i> , 2022, 65, 1436-1449.	6.3	13
8	Nutritional biomarkers and heart failure requiring hospitalization in patients with type 2 diabetes: the SURDIAGENE cohort. <i>Cardiovascular Diabetology</i> , 2022, 21, .	6.8	7
9	TOTUM63, a plant-based polyphenol-rich extract, improves glycaemic control in subjects with prediabetes or early stage newly-diagnosed type 2 diabetes in a randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2331-2340.	4.4	5
10	Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locus. <i>Cardiovascular Research</i> , 2021, 117, 600-612.	3.8	12
11	Euglycaemic ketoacidosis during gestational diabetes with concomitant COVID-19 infection. <i>Diabetes and Metabolism</i> , 2021, 47, 101181.	2.9	17
12	Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study. <i>Diabetes and Metabolism</i> , 2021, 47, 101202.	2.9	66
13	Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 391-403.	4.4	69
14	Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. <i>Diabetes and Metabolism</i> , 2021, 47, 101216.	2.9	65
15	Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study. <i>Diabetologia</i> , 2021, 64, 668-680.	6.3	12
16	Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. <i>Diabetologia</i> , 2021, 64, 778-794.	6.3	120
17	Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1162-1172.	4.4	33
18	Diabète et COVID-19: les leçons de CORONADO. <i>Medecine Des Maladies Metaboliques</i> , 2021, 15, 15-23.	0.1	2

#	ARTICLE	IF	CITATIONS
19	<i>ACE</i> I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1377-1384.	8.6	6
20	Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: Results from the CORONADO study. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108695.	2.8	19
21	Glucose-lowering treatments and COVID-19 mortality in T2DM. <i>Nature Reviews Endocrinology</i> , 2021, 17, 387-388.	9.6	7
22	Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (HSD17B14) with Reduced Progression to End Stage Kidney Disease in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2634-2651.	6.1	9
23	Do diabetic complications influence cancer-related events in people with type 2 diabetes? A cohort approach. <i>Diabetes and Metabolism</i> , 2021, 48, 101289.	2.9	0
24	Association of Urine Haptoglobin With Risk of All-Cause and Cause-Specific Mortality in Individuals With Type 2 Diabetes: A Transethnic Collaborative Work. <i>Diabetes Care</i> , 2020, 43, 625-633.	8.6	6
25	Association between sleep disturbances, fear of hypoglycemia and psychological well-being in adults with type 1 diabetes mellitus, data from cross-sectional VARDIA study. <i>Diabetes Research and Clinical Practice</i> , 2020, 160, 107988.	2.8	9
26	Comment on Chen et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. <i>Diabetes Care</i> 2020;43:1399-1407. <i>Diabetes Care</i> , 2020, 43, e163-e164.	8.6	7
27	Type 1 Diabetes in People Hospitalized for COVID-19: New Insights From the CORONADO Study. <i>Diabetes Care</i> , 2020, 43, e174-e177.	8.6	35
28	Relationship Between Diabetic Retinopathy Stages and Risk of Major Lower-Extremity Arterial Disease in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 2751-2759.	8.6	10
29	Blood glucose levels and COVID-19. Reply to Sardu C, D'Onofrio N, Balestrieri ML et al [letter] and Lepper PM, Bals R, JANI P et al [letter]. <i>Diabetologia</i> , 2020, 63, 2491-2494.	6.3	4
30	Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. <i>Diabetologia</i> , 2020, 63, 1500-1515.	6.3	638
31	Leukocyte Telomere Length, DNA Oxidation, and Risk of Lower-Extremity Amputation in Patients With Long-standing Type 1 Diabetes. <i>Diabetes Care</i> , 2020, 43, 828-834.	8.6	11
32	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1357-1368.	4.4	26
33	Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2371-2380.	3.6	35
34	Bisphenol A, Chlorinated Derivatives of Bisphenol A and Occurrence of Myocardial Infarction in Patients with Type 2 Diabetes: Nested Case-Control Studies in Two European Cohorts. <i>Environmental Science &amp; Technology</i> , 2019, 53, 9876-9883.	10.0	33
35	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2000-2016.	6.1	135
36	Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes. <i>Diabetes Care</i> , 2019, 42, 2290-2297.	8.6	15

#	ARTICLE	IF	CITATIONS
37	No association between fear of hypoglycemia and blood glucose variability in type 1 diabetes: The cross-sectional VARDIA study. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 554-560.	2.3	8
38	Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use. <i>Diabetologia</i> , 2019, 62, 939-947.	6.3	36
39	Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy. <i>Diabetes Care</i> , 2019, 42, 93-101.	8.6	37
40	Multiethnic Genome-Wide Association Study of Diabetic Retinopathy Using Liability Threshold Modeling of Duration of Diabetes and Glycemic Control. <i>Diabetes</i> , 2019, 68, 441-456.	0.6	54
41	Circulating Concentrations of Redox Biomarkers Do Not Improve the Prediction of Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	22
42	Plasma concentrations of 8-hydroxy-2â€²-deoxyguanosine and risk of kidney disease and death in individuals with type 1 diabetes. <i>Diabetologia</i> , 2018, 61, 977-984.	6.3	28
43	Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2018, 17, 110.	6.8	35
44	Prognostic Values of Inflammatory and Redox Status Biomarkers on the Risk of Major Lower-Extremity Artery Disease in Individuals With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 2162-2169.	8.6	14
45	Novel risk genes identified in a genome-wide association study for coronary artery disease in patients with type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2018, 17, 61.	6.8	29
46	T-cadherin gene variants are associated with nephropathy in subjects with type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1987-1993.	0.7	2
47	Association of Circulating Biomarkers (Adrenomedullin, TNFR1, and NT-proBNP) With Renal Function Decline in Patients With Type 2 Diabetes: A French Prospective Cohort. <i>Diabetes Care</i> , 2017, 40, 367-374.	8.6	43
48	The Genetic Landscape of Renal Complications in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 557-574.	6.1	101
49	Plasma Copeptin, Kidney Outcomes, Ischemic Heart Disease, and All-Cause Mortality in People With Long-standing Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 2288-2295.	8.6	51
50	ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients. <i>Diabetologia</i> , 2016, 59, 2321-2330.	6.3	30
51	Lower-extremity amputation as a marker for renal and cardiovascular events and mortality in patients with long standing type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2016, 15, 5.	6.8	20
52	Death, end-stage renal disease and renal function decline in patients with diabetic nephropathy in French cohorts of type 1 and type 2 diabetes. <i>Diabetologia</i> , 2016, 59, 208-216.	6.3	42
53	Glutathione peroxidase-1 gene (GPX1) variants, oxidative stress and risk of kidney complications in people with type 1 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 12-19.	3.4	37
54	Contribution of the low-frequency, loss-of-function p.R270H mutation in <i>FFAR4</i> ( <i>GPR120</i> ) to increased fasting plasma glucose levels. <i>Journal of Medical Genetics</i> , 2015, 52, 595-598.	3.2	29

#	ARTICLE	IF	CITATIONS
55	Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes. <i>Free Radical Biology and Medicine</i> , 2015, 86, 16-24.	2.9	14
56	Plasma Adrenomedullin and Allelic Variation in the <i>ADM</i> Gene and Kidney Disease in People With Type 2 Diabetes. <i>Diabetes</i> , 2015, 64, 3262-3272.	0.6	12
57	Association of Serum Concentration of TNFR1 With All-Cause Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease: Follow-up of the SURDIAGENE Cohort. <i>Diabetes Care</i> , 2014, 37, 1425-1431.	8.6	65
58	Hypomethylation of the promoter of the catalytic subunit of protein phosphatase 2A in response to hyperglycemia. <i>Physiological Reports</i> , 2014, 2, e12076.	1.7	6
59	Manganese Superoxide Dismutase (SOD2) Polymorphisms, Plasma Advanced Oxidation Protein Products (AOPP) Concentration and Risk of Kidney Complications in Subjects with Type 1 Diabetes. <i>PLoS ONE</i> , 2014, 9, e96916.	2.5	31
60	Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 1 diabetes. <i>Diabetologia</i> , 2013, 56, 2733-2742.	6.3	14
61	Plasma Copeptin and Renal Outcomes in Patients With Type 2 Diabetes and Albuminuria. <i>Diabetes Care</i> , 2013, 36, 3639-3645.	8.6	73
62	Prognostic Value of the Insertion/Deletion Polymorphism of the <i>ACE</i> Gene in Type 2 Diabetic Subjects. <i>Diabetes Care</i> , 2008, 31, 1847-1852.	8.6	66
63	Modulation of the Renal Response to ACE Inhibition by ACE Insertion/Deletion Polymorphism During Hyperglycemia in Normotensive, Normoalbuminuric Type 1 Diabetic Patients. <i>Diabetes</i> , 2005, 54, 2961-2967.	0.6	21
64	Different Patterns of Insulin Resistance in Relatives of Type 1 Diabetic Patients With Retinopathy or Nephropathy: The Genesis France-Belgium Study. <i>Diabetes Care</i> , 2004, 27, 2661-2668.	8.6	55
65	Prognostic Value of Angiotensin-I Converting Enzyme I/D Polymorphism for Nephropathy in Type 1 Diabetes Mellitus: A Prospective Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 541-549.	6.1	99